GlassScriptPhysician profile
Kambiz Shetabi
NPI 1972827806
$8,863.62
in general payments reported to CMS, 2019-2025
37 companies · $631 in 2025
The $631 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,349 · 2020: $434 · 2021: $2,048 · 2022: $1,495 · 2023: $1,035 · 2024: $872 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.34 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,218.83 | 2019-2024 | Aveir, Mitraclip, Confirm Rx |
| Medtronic Vascular, INC. | $1,175.45 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,075.89 | 2021-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $883.45 | 2019-2024 | Impella |
| Medtronic, INC. | $745.75 | 2021-2024 | Micra, Linq II, Crome Dr Mri Surescan |
| Boston Scientific Corporation | $455.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $397.08 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $389.23 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $345.20 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $321.44 | 2021-2025 | |
| Astellas Pharma US INC | $313.65 | 2019-2022 | |
| Pfizer INC. | $177.20 | 2021-2025 | |
| Cvrx, INC. | $125.66 | 2021-2025 | Barostim Neo System |
| Novo Nordisk INC | $121.72 | 2021-2025 | Rybelsus, Ozempic |
| Biosense Webster, INC. | $113.55 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $112.27 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $91.08 | 2022-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $84.98 | 2024 | |
| Novartis Pharmaceuticals Corporation | $78.67 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $62.46 | 2020-2021 | |
| Biotronik INC. | $61.44 | 2021-2022 | |
| Esperion Therapeutics, INC. | $52.55 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $46.10 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $45.42 | 2024 | Zio Xt Patch, Zio Monitor |
| Amgen INC. | $45.12 | 2019-2024 | Repatha |
| Cardiovascular Systems INC. | $44.34 | 2021 | |
| Cardiva Medical, INC. | $39.76 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $37.90 | 2025 | Amvuttra |
| Atricure, INC. | $37.46 | 2021 | |
| Tactile Systems Technology INC | $31.58 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $26.80 | 2024 | |
| Glaxosmithkline, LLC. | $21.15 | 2025 | Arexvy |
| Bridgebio Pharma, INC. | $20.81 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $20.20 | 2022 | |
| Akcea Therapeutics, INC. | $19.73 | 2021 | |
| Chiesi USA, INC. | $14.06 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $9.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kambiz Shetabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.